Effect of neoadjuvant chemotherapy combined with hyperthermic intraperitoneal perfusion chemotherapy on advanced gastric cancer.
Effect of neoadjuvant chemotherapy combined with hyperthermic intraperitoneal perfusion chemotherapy on advanced gastric cancer.
复制标题
DOI：
10.3892/etm.2014.1599
复制
发表时间：
2014-05
影响因子：
2.7
通讯作者：
Wang ZY
中科院分区：
文献类型：
--
作者：
Cui HB;Ge HE;Bai XY;Zhang W;Zhang YY;Wang J;Li X;Xing LP;Guo SH;Wang ZY
新辅助和热腹腔化疗已被证明可有效治疗可切除的晚期胃癌。本研究旨在探讨新辅助化疗联合腹腔热灌注化疗治疗术后进展期胃癌的临床有效性和安全性。 192例确诊为进展期胃癌的患者随机分为4组（每组48例）：对照组、新辅助化疗组、热腹腔灌注化疗组和联合组。联合组接受新辅助化疗联合腹腔热灌注化疗。观察并发症、不良反应、2年内复发率以及术后1年、3年生存率。四组间I~II度骨髓抑制、III~IV度骨髓抑制、I~II度恶心或III~IV度恶心呕吐发生率比较，差异无统计学意义（P>0.05）。对照组、新辅助化疗组、腹腔热灌注化疗组和联合组的中位无进展生存时间分别为26、31、33和28个月（P<0.001）。与对照组相比，联合组2年无复发生存率显着降低（P=0.04）。四组中位生存时间差异有统计学意义（P=0.001）。联合组1年生存率显着高于对照组，差异有统计学意义（P=0.03）。但四组的1年生存率差异无统计学意义（P>0.05）。与对照组相比，其他三组的3年生存率显着较高（P<0.05）。因此，本研究结果表明，新辅助化疗联合腹腔热灌注化疗治疗晚期胃癌具有良好的耐受性，且依从性和效率有所提高。
Neoadjuvant and hyperthermic intraperitoneal chemotherapies have been shown to be effective in the treatment of resectable advanced gastric cancer. The aim of the present study was to investigate the clinical efficiency and security of neoadjuvant chemotherapy in combination with hyperthermic intraperitoneal chemotherapy for the treatment of postoperative advanced gastric cancer. A total of 192 patients diagnosed with advanced gastric cancer were randomly divided into the following four groups (n=48 per group): Control, neoadjuvant chemotherapy, hyperthermic intraperitoneal perfusion chemotherapy and joint groups. The joint group received neoadjuvant chemotherapy combined with hyperthermic intraperitoneal perfusion chemotherapy. Complications, adverse reactions, recurrence rates within 2 years and the 1- and 3-year survival rates following surgery were observed. No significant differences were observed in the occurrence rates of I–II degree myelosuppression, III–IV degree myelosuppression, I–II degree nausea or III–IV degree nausea and vomiting among the four groups (P>0.05). The median progression-free survival times were 26, 31, 33 and 28 months in the control, neoadjuvant chemotherapy, hyperthermic intraperitoneal perfusion chemotherapy and joint groups, respectively (P<0.001). Compared with the control group, the recurrence-free 2-year survival rate of the joint group was significantly lower (P=0.04). The difference among the median survival times of the four groups was statistically significant (P=0.001). The 1-year survival rate of the joint group was significantly higher when compared with the control group and the difference was statistically significant (P=0.03). However, no statistically significant difference was identified among the 1-year survival rates of the four groups (P>0.05). Compared with the control group, the 3-year survival rates of the other three groups were significantly higher (P<0.05). Therefore, the results of the present study indicated that neoadjuvant chemotherapy combined with hyperthermic intraperitoneal perfusion chemotherapy for the treatment of advanced gastric cancer is well tolerated and exhibits improved compliance and efficiency.
登录
查看更多内容
影响因子：
8.4
作者：
Eisenhauer, E. A.;Therasse, P.;Verweij, J.
通讯作者：
Verweij, J.
影响因子：
2.5
作者：
Bozzetti, F.;Yu, W.;Deraco, Marcello
通讯作者：
Deraco, Marcello
DOI：
10.1046/j.1525-1438.2001.11(suppl.1)sup1057.x
发表时间：
2001-01-01
影响因子：
4.8
作者：
Hager, ED;Dziambor, H;Strama, H
通讯作者：
Strama, H
影响因子：
45.3
作者：
Ychou, Marc;Boige, Valerie;Rougier, Philippe
通讯作者：
Rougier, Philippe
影响因子：
3.7
作者：
Tsilimparis, Nikolaos;Bockelmann, Christina;Hartmann, Jens
通讯作者：
Hartmann, Jens